UT HEALTH CENTER AT TYLER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $9.7M
- Transactions
- 1,999
- Companies
- 40
- Average per transaction
- $4,860
Who reported the payments
| Insmed, Inc. | $2,188,063 |
| Seagen Inc. | $1,556,985 |
| Boehringer Ingelheim | $807,084 |
| Genentech, Inc. | $747,400 |
| E.r. Squibb & Sons, L.L.C. | $460,567 |
| Merck | $441,893 |
| Argenx US, Inc. | $381,271 |
| Regeneron | $334,715 |
| Paratek Pharmaceuticals, Inc. | $271,131 |
| Grifols Therapeutics LLC | $200,300 |
| AstraZeneca | $196,047 |
| EMD Serono, Inc. | $156,828 |
| Daiichi Sankyo Inc. | $147,810 |
| Pfizer | $132,542 |
| Vertex | $122,596 |
| CSL Behring | $117,417 |
| Gilead | $103,905 |
| Takeda Pharmaceuticals U.S.A., Inc. | $96,952 |
| Medtronic | $93,286 |
| Janssen Research & Development, LLC | $81,442 |
| Sanofi US Services Inc. | $80,952 |
| Electromed, Inc. | $80,405 |
| Astrazeneca UK Limited | $75,850 |
| F. Hoffmann-la Roche AG | $59,937 |
| Gynesonics, Inc. | $55,817 |
| Abiomed | $55,103 |
| Melinta Therapeutics, LLC | $54,019 |
| AbbVie | $47,535 |
| Astellas Pharma Global Development | $39,513 |
| AVEO Pharmaceuticals, Inc. | $39,270 |
| Hill-rom Company, Inc | $37,319 |
| Beigene, Ltd. | $35,760 |
| Helsinn Healthcare SA | $33,450 |
| Ipsen Bioscience Inc. | $29,200 |
| SPR Therapeutics, Inc | $29,199 |
| Amgen | $28,714 |
| Paragon 28, Inc. | $25,253 |
| Epizyme, Inc. | $23,991 |
| Clovis Oncology, Inc. | $23,100 |
| Mallinckrodt Enterprises LLC | $22,813 |